The Cell and Gene Therapy (CGT) Catapult (London, UK) will support three UK site specializing in the delivery of cell and gene therapy products. The centers – Innovate Manchester Advanced Therapy Centre Hub, the Midlands-Wales Advanced Therapy Treatment Centre (comprising Birmingham, Wales and Nottingham) and the Northern Alliance Advanced Therapies Treatment Centre (comprising Scotland, Newcastle and Leeds) – are funded by Innovate UK (UK) as joint ventures including industry, academic and NHS partners.
The centers will work together to increase national patient access to advanced therapies and establish best practice for the near-patient manufacturing, and safe and effective delivery of those therapies through the creation of robust, integrated supply chains with systems for the tracking of both products and patients. This type of integrated system will be the first established in the UK and will position the country as a leader in the delivery of clinical trials and the routine clinical delivery of cell and gene therapies as well as providing vital data to support reimbursement and payment systems.
Learn more about the Cell and Gene Therapy Catapult on RegMedNet:
“This network represents the continued progress of advanced therapies from the lab to the patient,” commented Keith Thompson, Chief Executive Officer, CGT Catapult. “We are excited to be playing a key role in increasing patient access to these potentially life-changing therapies as well as further establishing best practice in their safe and effective delivery.
“We will help to join up manufacturing centers to these new treatment centers and establish new vein to vein clinical pathways. Our manufacturing center, which will open fully in 2018, is expected to help pave the way, at scale, for the industrialization and commercialization of cell and gene medicines.”
Ruth McKernan, Chief Executive of Innovate UK, said: “Innovate UK’s investment in the Advanced Therapies Treatment Centers is a crucial component of the government’s modern industrial strategy. They will support the deployment of cutting edge cell and gene science to tackle some of the most debilitating conditions that patients face today. These centers will also help to maintain and boost the UK’s global leadership in this sector, delivering new revenue and growth for the healthcare economy.”
Source: CGT Catapult press release